Abstract
Malignant transformations, such as ovarian squamous cell carcinoma (SCC) in ovarian mature cystic teratoma (OMCT), are rare tumors. The management of recurrent disease is still a challenge, and the gene mutations involved remain unclear. We herein report a recurrent case of ovarian SCC with a PIK3CA gene variation and immunohistochemical staining of programmed death-ligand 1 (PD-L1) >10%. This patient achieved clinical remission after platinum-based effective chemotherapy and programmed death 1 (PD-1) immunotherapy.
Highlights
Malignant transformation, such as ovarian squamous cell carcinoma (SCC) in ovarian mature cystic teratoma (OMCT), is a rare tumor
We report a recurrent case of ovarian SCC with a PIK3CA gene variation and immunohistochemical staining of programmed death-ligand 1 (PD-L1) >10%
Malignant transformation occurs in 1%–2% of OMCTs, and the majority of these (80%) are SCCs [1]
Summary
Malignant transformation, such as ovarian squamous cell carcinoma (SCC) in ovarian mature cystic teratoma (OMCT), is a rare tumor. We report a recurrent case of ovarian SCC with a PIK3CA gene variation and immunohistochemical staining of programmed death-ligand 1 (PD-L1) >10% This patient achieved clinical remission after platinum-based effective chemotherapy and programmed death 1 (PD-1) immunotherapy. At the seventh month of sirolimus, serum Scc-Ag elevated to 3.7 ng/ml, and CT showed lung metastasis in April 2020 Considering the second recurrence of the tumor and given the tumor’s PD-L1 positivity, six cycles of platinum-based chemotherapy (Taxol 175 mg/m2 and cisplatin 70 mg/m2, intravenously every 3 weeks) plus PD-1 inhibitor (sintilimab injection, 200 mg, intravenously every 3 weeks) were administered after a discussion at the multidisciplinary tumor board.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
